A Randomized, Multicenter, Open Label, Comparative Study to Evaluate the Immunogenicity and Reactogenicity of a New Fully Liquid Hexavalent DTwP-Hepb-Hib-IPV Vaccine (EasysixTM, Panacea Biotec Ltd.) with Pentavalent DTwP-Hepb/Hib Vaccine (Tritanrix-HBTM Reconstituted with HiberixTM, GSK) Co Administered with Imovax Polio (Salk Based Inactivated Polio Vaccine; sanofi pasteur India Pvt. Ltd.) in Healthy Infants.

Trial Profile

A Randomized, Multicenter, Open Label, Comparative Study to Evaluate the Immunogenicity and Reactogenicity of a New Fully Liquid Hexavalent DTwP-Hepb-Hib-IPV Vaccine (EasysixTM, Panacea Biotec Ltd.) with Pentavalent DTwP-Hepb/Hib Vaccine (Tritanrix-HBTM Reconstituted with HiberixTM, GSK) Co Administered with Imovax Polio (Salk Based Inactivated Polio Vaccine; sanofi pasteur India Pvt. Ltd.) in Healthy Infants.

Completed
Phase of Trial: Phase III

Latest Information Update: 02 Sep 2016

At a glance

  • Drugs Hib-DTP-hepatitis B-poliovirus vaccine (Primary) ; Hib-DTP hepatitis B vaccine (Tritanrix-HepB/Hiberix); Poliovirus vaccine
  • Indications Haemophilus infections; Hepatitis B; Pertussis; Poliomyelitis; Tetanus
  • Focus Pharmacodynamics
  • Sponsors Panacea Biotec
  • Most Recent Events

    • 24 Feb 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top